Amadeus Capital Partners www.amadeuscapital.com, a global technology investor has invested in Inotec AMD www.inotecamd.com a maker of mobile medical devices designed to heal chronic hypoxic wounds. More than 90 percent of wounds suffer from a lack of oxygen but with the launch of NATROX™ an advanced wound care technology, this serious concern will be addressed.
Inotec’s compact, portable, and wearable NATROX system CE marked and FDA approved provides a continuous supply of pure humidified oxygen to wounds. In preliminary trials, the treatment has been shown to reduce the size of chronic wounds substantially within weeks with a large number of patients with their wounds healing completely. NATROX can be used at home as well as in hospitals, which will alleviate pressure on healthcare systems.
Amadeus will invest and provide their expertise to Inotec based in Cambridge UK to enable the company to carry out large scale clinical trials outside the UK. The plan is to broaden the application of NATROX and help establish commercial agreements to grow the company’s presence internationally.
According to Trevor Stanley, Inotec CEO, “The global wound care market is projected to grow to $18.3 billion globally in 2019, driven in part by changing life styles and an aging population in many countries. Also, there are 400 million diabetics of which 60 million are likely to develop a lower limb ulcers and sores.